TY  - JOUR
AU  - Bendell, Johanna C.
AU  - Sauri, Tamara
AU  - Cubillo Gracian, Antonio
AU  - Alvarez, Rafael
AU  - Lopez-Lopez, Carlos
AU  - Garcia-Alfonso, Pilar
AU  - Hussein, Maen
AU  - Limon Miron, Maria-Luisa
AU  - Cervantes, Andres
AU  - Montagut, Clara
AU  - Santos Vivas, Cristina
AU  - Bessudo, Alberto
AU  - Plezia, Patricia
AU  - Moons, Veerle
AU  - Andel, Johannes
AU  - Bennouna, Jaafar
AU  - van der Westhuizen, Andre
AU  - Samuel, Leslie
AU  - Rossomanno, Simona
AU  - Boetsch, Christophe
AU  - Lahr, Angelika
AU  - Franjkovic, Izolda
AU  - Heil, Florian
AU  - Lechner, Katharina
AU  - Krieter, Oliver
AU  - Hurwitz, Herbert
AU  - McCAVE Study Grp
PY  - 2019
DO  - 10.1634/theoncologist.2019-0291
SN  - 1083-7159
UR  - https://hdl.handle.net/10668/27428
T2  - Oncologist
AB  - Background Bevacizumab, a VEGF-A inhibitor, in combination with chemotherapy, has proven to increase progression-free survival (PFS) and overall survival in multiple lines of therapy of metastatic colorectal cancer (mCRC). The angiogenic factor...
LA  - en
PB  - Wiley
KW  - First-line metastatic colorectal cancer
KW  - Angiopoetin-2
KW  - VEGF-A
KW  - Vanucizumab
KW  - Bevacizumab
KW  - Antitumor-activity
KW  - Clinical-outcomes
KW  - Phase-ii
KW  - Amg 386
KW  - Angiopoietin-2
KW  - Combination
KW  - Antibody
KW  - Hypertension
KW  - Oxaliplatin
KW  - Biomarker
TI  - The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)
TY  - research article
VL  - 25
ER  -